Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia
Year: 2015
Type: article
Abstract: Several studies have shown that allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR1) of AML reduces the risk of relapse and improves relapse-free survival in intermediate- and poor-risk AML.[1][1] Benefits in (overall) survival are less obvious.[1][1],[2][2] One
Source: Haematologica
Institutions: University of Washington, Fred Hutch Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funder: National Cancer Institute
OpenAlex ID: W2118267019